Myxoid pattern in smooth muscle tumor of uncertain malignant potential (STUMP) is a significant prognostic parameter with difficult diagnostic dilemmas

Background: Uterine smooth muscle tumors of uncertain malignant potential (STUMPs) represent a heterogeneous group of tumors with varying histological and biological characteristics. Tumors featuring a dominant myxoid stroma are uncommon in the uterus. This case emphasizes the importance of recognizing the myxoid pattern in smooth muscle tumors, especially within the STUMP category. Case: In this study, we present a 39-year-old woman with a large transmural intrauterine nodule. The findings indicated smooth muscle tumor tissue with a fascicular pattern, without significant ischemic necrosis or cytological pleomorphism. The mitotic count was 1/10 High Power Field (HPF). The tumor exhibited more than 50% myxoid histomorphology, indicative of a rare and specific type of smooth muscle differentiation. Immunohistochemical analysis showed positive reactions for smooth muscle differentiation, retained progesterone receptor expression, and no aberrant tumor protein p53 (p53) or cyclin-dependent kinase inhibitor 2A (p16) expressions. The marker of proliferation Ki-67 was low. Considering all the characteristics, this myxoid smooth muscle tumor was diagnosed as a STUMP myxoid neoplasm. The patient underwent a hysterectomy with bilateral salpingectomy and bilateral ovarian conservation. The patient is currently under follow-up and has not experienced any complications. Conclusions: This case illustrates an extremely rare instance of STUMP, which continues to pose challenges in both diagnosis and treatment. Myxoid patterns are exceptionally uncommon and often hard to detect, making them surprising in smooth muscle tumors. Recognizing this distinct differentiation is crucial, as accurate diagnostic criteria must be applied during the histopathological evaluation of these tumors. The presence of a myxoid pattern suggests a worse prognosis, highlighting the need for more vigilant follow-up in these patients.

Myxoid; STUMP; Uterus

[1] Devereaux KA, Kunder CA, Longacre TA. ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors. The American Journal of Surgical Pathology. 2019; 43: 64–74.

[2] PPC, Croce S, Gupta M. Smooth muscle tumour of uncertain malignant potential of the uterine corpus. In WHO Classification of Tumours Editorial Board (eds.) Female genital tumors: WHO classification of tumours, vol. 4 (pp. 279–280). 5th edn. International Agency for Research on Cancer: Lyon. 2020.

[3] Rizzo A, Ricci AD, Saponara M, DE Leo A, Perrone AM, DE Iaco P, et al. Recurrent uterine smooth-muscle tumors of uncertain malignant potential (STUMP): state of the art. Anticancer Research. 2020; 40: 1229–1238.

[4] Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology. 2018; 73: 284–298.

[5] Şahin H, Karatas F, Coban G, Özen Ö, Erdem Ö, Onan MA, et al. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes. Journal of Gynecologic Oncology. 2019; 30: e54.

[6] Liu L, Xiao Z, Li Z, Zheng J, Xu X, Zhou H. Uterine smooth muscle tumors of uncertain malignant potential: a 13-year retrospective study. Frontiers in Oncology. 2024; 14: 1458968.

[7] Istrate-Ofiţeru AM, Zorilă GL, Ruican D, Petrescu AM, Berbecaru EIA, Roşu GC, et al. Uterine myxoid leiomyosarcoma—a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation. Romanian Journal of Morphology and Embryology. 2021; 62: 883–896.

[8] Al Khader A, Nsour E, Abdallat AN. Perinodular hydropic degeneration in uterine leiomyoma causing rapid enlargement and mimicking a myxoid smooth muscle tumor: case report of a diagnostic challenge. Case Reports in Women’s Health. 2019; 24: e00150.

[9] Di Giuseppe J, Grelloni C, Giuliani L, Delli Carpini G, Giannella L, Ciavattini A. Recurrence of uterine smooth muscle tumor of uncertain malignant potential: a systematic review of the literature. Cancers. 2022; 14: 2323.

[10] Borella F, Cosma S, Ferraioli D, Ray-Coquard I, Chopin N, Meeus P, et al. Clinical and histopathological predictors of recurrence in uterine smooth muscle tumor of uncertain malignant potential (STUMP): a multicenter retrospective cohort study of tertiary centers. Annals of Surgical Oncology. 2022; 29: 8302–8314.

[11] Zhang C, Gao J, Lu S, Zhang Y, Zhu H. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a retrospective study in a single center. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2021; 265: 74–79.

[12] El Hassouni F, Tligui S, Lakhdissi A, Rouas L, El Youssfi M. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a case report. International Journal of Surgery Case Reports. 2024; 118: 109607.

[13] Amal C, Fadwa A, Aicha G, Boufetal H, Mahdaoui S, Samouh N. Uterine smooth muscle tumor of uncertain malignant potential (STUMP) ABOUT a CASE. International Journal of Surgery Case Reports. 2024; 117: 109556.

[14] Aminzadeh P, Alibrahim E, Dobrotwir A, Paul E, Goergen S. Multiparametric MR evaluation of uterine leiomyosarcoma and STUMP versus leiomyoma in symptomatic women planned for high frequency focussed ultrasound: accuracy of imaging parameters and interobserver agreement for identification of malignancy. The British Journal of Radiology. 2021; 94: 20200483.

[15] Cotrino I, Carosso A, Macchi C, Baima Poma C, Cosma S, Ribotta M, et al. Ultrasound and clinical characteristics of uterine smooth muscle tumors of uncertain malignant potential (STUMPs). European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2020; 251: 167–172.

[16] Travaglino A, Raffone A, Gencarelli A, Neola D, Oliviero DA, Alfano R, et al. p53, p16 and Ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP). Pathology, Research and Practice. 2021; 226: 153592.

[17] Busca A, Parra-Herran C. Myxoid mesenchymal tumors of the uterus: an update on classification, definitions, and differential diagnosis. Advances in Anatomic Pathology. 2017; 24: 354–361.

[18] Tinelli A, D’Oria O, Civino E, Morciano A, Hashmi AA, Baldini GM, et al. Smooth muscle tumor of uncertain malignant potential (STUMP): a comprehensive multidisciplinary update. Medicina. 2023; 59: 1371.

[19] Liu HT, Wong CN, Wong CN, Liu FS. Uterine smooth muscle tumor of uncertain malignant potential: a review of current knowledge. Taiwanese Journal of Obstetrics & Gynecology. 2022; 61: 935–940.

[20] Lewis N, Soslow RA, Delair DF, Park KJ, Murali R, Hollmann TJ, et al. ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology. 2018; 31: 674–684.

[21] Yoon JY, Mariño-Enriquez A, Stickle N, de Borja RJ, Ismiil N, Djordjevic B, et al. Myxoid smooth muscle neoplasia of the uterus: comprehensive analysis by next-generation sequencing and nucleic acid hybridization. Modern Pathology. 2019; 32: 1688–1697.

[22] Michal M, Agaimy A, Croce S, Mechtersheimer G, Gross JM, Xing D, et al. PLAG1-rearranged uterine sarcomas: a study of 11 cases showing a wide phenotypical spectrum not limited to myxoid leiomyosarcoma-like morphology. Modern Pathology. 2024; 37: 100552.

[23] Li WQ, Wu HX, Li HB, Shen Y. Uterine myxoid leiomyosarcoma: identification of a novel PLAG1 fusion partner. Pathology. 2024; 56: 753–755.

[24] Tsakiridis I, Kalogiannidis I, Mamopoulos A, Dagklis T, Nikolaidou C, Athanasiadis A. Giant uterine STUMP in pregnancy: a rare case report with preservation of fertility. Hippokratia. 2021; 25: 169–171.

[25] Huo L, Wang D, Wang W, Cao D, Yang J, Wu M, et al. Oncologic and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single center retrospective study of 67 cases. Frontiers in Oncology. 2020; 10: 647.

[26] Bucuri CE, Ciortea R, Malutan AM, Oprea V, Toma M, Roman MP, et al. Smooth muscle tumor of uncertain malignant potential (STUMP): a systematic review of the literature in the last 20 years. Current Oncology. 2024; 31: 5242–5254.

[27] Croce S, Ribeiro A, Brulard C, Noel JC, Amant F, Stoeckle E, et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Modern Pathology. 2015; 28: 1001–1010.

[28] Croce S, Ducoulombier A, Ribeiro A, Lesluyes T, Noel JC, Amant F, et al. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Modern Pathology. 2018; 31: 816–828.

[29] Lapresa-Alcalde MV, Ruiz-Navarro MJ, Sancho de Salas M, Cubo AM. A review and follow-up of uterine smooth muscle tumours of uncertain malignant potential (STUMP): a case series and literature review. Diseases. 2023; 11: 99.

[30] Jena S, Sinha NK, Mishra M, Singh V, Kumar Upadhyay A. Uterine smooth muscle tumor of undetermined malignant potential (STUMP): a diagnostic challenge. Cureus. 2024; 16: e73115.